Global access potential OncoGenesis aims to enable cervical cancer screening globally, including resource-limited regions. This presents sales opportunities for international distributors, telemedicine partners, and NGO collaborations to expand deployment of the iPap self-collection device and CerMark tests in underserved markets.

Home collection adoption The iPap self-collection device enables at-home sample collection, opening conversations with healthcare providers and payers about remote screening programs, home-based kits, and patient-led testing initiatives that can drive higher screening uptake.

Early-stage collaboration Past collaboration with Quanterix signals openness to biomarker-driven, quantitative diagnostics. There are sales opportunities to partner with diagnostics companies, labs, and research institutions to co-develop and validate CerMark for LAB and subsequent POC deployment.

Funding readiness cues With sub-$1M revenue and modest funding, there is a clear pathway for government grant programs, social impact funds, and accelerator support targeting women's health and cervical cancer screening to accelerate market entry and scale.

Strategic leadership edge New CEO Teresa Prego brings leadership momentum; leverage this to position OncoGenesis for strategic pilots, regional market launches, and channel partnerships with healthcare providers, labs, and regional distributors to accelerate adoption.